Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04379011 · ClinicalTrials.gov registry record · Phase 1
Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury
A Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04379011 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 24 participants.
The verdict
NCT04379011, a Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Spinal cord injury (SCI) is associated with severe neuropathic pain that is often refractory to all pharmacological intervention. Preliminary data suggest brivarecetum is a mechanism-based pharmacological intervention for neuropathic pain in SCI. This randomized, placebo-controlled pilot clinical trial will assess feasibility of a 3-month treatment course with brivarecetum.
Interventions
- OTHER Placebo
- DRUG Brivaracetam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2024-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04379011
The ClinicalTrials.gov registry entry for NCT04379011 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04379011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04379011 about?
NCT04379011 is a clinical study titled "Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury". Spinal cord injury (SCI) is associated with severe neuropathic pain that is often refractory to all pharmacological intervention. Preliminary data suggest brivarecetum is a mechanism-based pharmacological intervention for neuropathic pain in SCI. This randomized, placebo-controlled pilot clinical tr...
What is the current status of trial NCT04379011?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-02-01. Estimated completion is 2024-09-01.
What interventions are being tested in trial NCT04379011?
The interventions under investigation include: Placebo (OTHER), Brivaracetam (DRUG).
Who is sponsoring clinical trial NCT04379011?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.